Supplementary material to

SARS-CoV-2 Neutralization in Commercial Lots of Plasma-derived Immunoglobulin

Volk, Andreas[1+#]; Covini-Souris, Caroline[2#]; Kuehnel, Denis[1]; De Mey, Christian[3], Römisch, Jürgen [2*]; Schmidt, Torben[1*]

1: Octapharma Biopharmaceuticals® GmbH, Virus and Prion Validation, Frankfurt, Germany

2: Octapharma® Pharmazeutika Produktionsgesellschaft m.b.H., R&D Plasma, Vienna, Austria

3: ACPS-Network GmbH, Wiesbaden, Germany

#: Both authors contributed equally

*: Both authors contributed equally

+: Please address correspondence to: andreas.volk@octapharma.com



Potency Assay Format - Performance		Internal Std. V	Internal Std. O	WHO International Std. I
Precision	Mean [1:x]	3067	4922	2199
	Standard Deviation [1:x]	703	804	379
	Coefficient of Variation	0.33	0.16	0.17
Linearity	R^2	0.97	0.95	0.91
Accuracy	Assigend Potency [IU]	1439	2017	1000
	Recovery	n.a.	n.a.	105.40%

Screening Assay Format - Performance		Internal Std. V
Precision	Mean [1:x]	3067
	Standard Deviation [1:x]	1017
	Coefficient of Variation	33%
Linearity	R^2	0.98
Accuracy	Assigned Potency	
	Recovery	not done

Supp.Fig. 1 Retrospective SARS-CoV-2 microneutralization assay characteristics for potency assay format (**a-c**) and screening assay format (**d-f**). **a** and **d** intermediate precision of internal standards O and V measured as fold dilution as calibrator in each experimental run. **b** and **e** linearity data of the two assay formats. Depicted is the mean result ± SD per dilution level for each standard tested. **c** and **f** tabular results of retrospective analyses on potency and screening assay formats for precision, linearity and accuracy, where applicable



Supp. Fig. 3: PK data processing for superposition analyses. **a** reference dataset of the observed individual time courses of untransformed IgG-levels on 4-weekly repeated dosing of IVIG (median dose: 0.406 g/kg-BW) [40]. **b** individual time courses of the baseline-adjusted IgG-levels on 4-weekly dosing of IgG. **c** reference single-dose profiles, i.e. time courses of the median, 25th (P25), and 75th (p75) percentiles of the data from panel b dose-normalized by g/kg-BW. **d** approximated time courses of the dose-normalized IgG-levels (mg/ml per g/kg-BW dosed) throughout ten 4-weekly repeated doses of IVIG derived from the median, P25 and P75 reference profiles (see panel c) using a superposition cascade with time-staggered dosing